Department of Lymphatic Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences（Zhejiang Cancer Hospital）, Hangzhou, China.
Department of Lymphatic Medical Oncology, Institute of Cancer and Basic Medicine（IBMC）, Chinese Academy of Sciences, Hangzhou, China.
J Clin Lab Anal. 2020 Sep;34(9):e23399. doi: 10.1002/jcla.23399. Epub 2020 Jul 1.
The present study aimed to explore the association of long non-coding RNA nuclear paraspeckle assembly transcript 1 (lncRNA NEAT1) with multiple myeloma (MM) risk and further investigate its correlation with clinical features, treatment response, survival profiles, and its interaction with microRNA-125a (miR-125a) in MM patients.
Totally, 114 de novo symptomatic MM patients and 30 healthy donors (as controls) were recruited. Their bone marrow samples were collected before treatment (MM patients) and at enrollment (healthy donors), respectively. Subsequently, plasma cells were isolated from bone marrow for detection of lncRNA NEAT1 and miR-125a expression via reverse transcription quantitative polymerase chain reaction.
lncRNA NEAT1 was upregulated in MM patients compared with healthy donors and presented with excellent value in distinguishing MM patients from healthy donors. In MM patients, lncRNA NEAT1 positively associated with International Staging System (ISS) stage, beta-2 microglobulin (β2-MG), and lactate dehydrogenase (LDH), but not correlated with core cytogenetics and other clinical features. Furthermore, lncRNA NEAT1 negatively associated with complete remission (CR), overall remission rate (ORR), progression-free survival (PFS), and overall survival (OS). Moreover, lncRNA NEAT1 negatively associated with miR-125a in MM patients. MiR-125a was downregulated in MM patients compared with healthy donors, and it negatively associated with ISS stage, β2-MG, and LDH, but positively correlated with CR, ORR, PFS, and OS in MM patients.
lncRNA NEAT1 might interact with miR-125a, and serves as a novel biomarker for treatment response and survival profiles in MM, indicating its clinical value for MM management.
本研究旨在探讨长链非编码 RNA 核斑组装转录本 1（lncRNA NEAT1）与多发性骨髓瘤（MM）风险的关联，并进一步研究其与 MM 患者临床特征、治疗反应、生存状况的相关性，以及与 microRNA-125a（miR-125a）的相互作用。
共纳入 114 例初治症状性 MM 患者和 30 名健康供者（作为对照）。分别在治疗前（MM 患者）和入组时（健康供者）采集骨髓样本，从骨髓中分离浆细胞，通过逆转录定量聚合酶链反应检测 lncRNA NEAT1 和 miR-125a 的表达。
与健康供者相比，MM 患者的 lncRNA NEAT1 表达上调，且在区分 MM 患者和健康供者方面具有良好的价值。在 MM 患者中，lncRNA NEAT1 与国际分期系统（ISS）分期、β2-微球蛋白（β2-MG）和乳酸脱氢酶（LDH）呈正相关，而与核心细胞遗传学和其他临床特征无关。此外，lncRNA NEAT1 与完全缓解（CR）、总缓解率（ORR）、无进展生存期（PFS）和总生存期（OS）呈负相关。此外，lncRNA NEAT1 与 MM 患者中的 miR-125a 呈负相关。与健康供者相比，MM 患者中 miR-125a 表达下调，与 ISS 分期、β2-MG 和 LDH 呈负相关，而与 CR、ORR、PFS 和 OS 呈正相关。
lncRNA NEAT1 可能与 miR-125a 相互作用，作为 MM 治疗反应和生存状况的新型生物标志物，提示其在 MM 管理中的临床价值。
